David Bonderman, the colorful yet publicity-shy co-founder of Fort Worth-based private equity titan TPG Inc. who became a billionaire by spearheading ...

David Bonderman, the colorful yet publicity-shy co-founder of private equity titan TPG who became a billionaire by spearheading massive company takeovers, bailouts of foundering enterprises and ...

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...

Pharma company Gilead Sciences has been awarded a massive $31.8 million in damages in connection with a lawsuit claiming ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Gilead Sciences’ top money maker Biktarvy has been the company’s crown jewel for years now, but with the HIV med inching ...

By far, the largest acquisition of 2024 was Novo Holdings' yet-to-be-closed buyout of manufacturer Catalent at $16.5 billion.

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.34 which represents a slight increase of $1.75 or 1.93% from the prior close of $90.59. The stock opened at $91.35 and ...

In a report released today, Michael Yee from Jefferies maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Courtney ...

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...

The work is a secondary analysis of the phase 3 Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), which demonstrated that the cholesterol-lowering medication pitavastatin reduced the risk ...